| Entry |
|
|---|
| Name |
Palbociclib (JAN/USAN);
Ibrance (TN)
|
|---|
| Product |
|
|---|
| Formula |
C24H29N7O2
|
|---|
| Exact mass |
447.2383
|
|---|
| Mol weight |
447.5328
|
|---|
| Structure |
   |
|---|
| Simcomp |
 |
|---|
| Class |
Antineoplastic
DG02943 CDK4/6 inhibitor
|
|---|
| Remark |
| Therapeutic category: | 4291 |
| Product (DG01831): | D10372<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Cyclin-dependent kinase (CDK) inhibitor |
|---|
| Disease |
Breast cancer (HR-positive, HER2-negative) [DS: H00031] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XE Protein kinase inhibitors
L01XE33 Palbociclib
D10372 Palbociclib (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Palbociclib
D10372 Palbociclib (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D10372 Palbociclib (JAN/USAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
Serine/threonine kinases
CMGC group
CDK4/6
D10372 Palbociclib (JAN/USAN) <JP/US>
Antineoplastics [br08340.html]
D10372
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10372
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10372
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10372
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10372
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D10372
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 33
1 C1x C 26.9500 -22.2600
2 N1x N 26.9500 -20.8600
3 C1x C 25.6900 -20.1600
4 C1x C 24.5000 -20.8600
5 N1y N 24.5000 -22.2600
6 C1x C 25.6900 -22.9600
7 C8y C 23.2400 -23.0300
8 C8x C 22.0500 -22.3300
9 C8x C 20.8600 -23.0300
10 C8y C 20.8600 -24.4300
11 N5x N 22.0500 -25.1300
12 C8x C 23.2400 -24.4300
13 N1b N 19.6000 -25.1300
14 C8y C 18.4100 -24.4300
15 N5x N 18.4100 -22.9600
16 C8y C 17.2200 -22.2600
17 C8y C 15.9600 -22.9600
18 C8x C 15.9600 -24.4300
19 N5x N 17.2200 -25.1300
20 N4y N 17.2200 -20.8600
21 C8y C 15.9600 -20.1600
22 C8y C 14.7700 -20.8600
23 C8y C 14.7700 -22.2600
24 C1y C 18.4100 -20.1600
25 C5a C 13.5800 -20.1600
26 C1a C 12.3900 -20.8600
27 O5a O 13.5800 -18.7600
28 O5x O 15.9600 -18.7600
29 C1a C 13.5800 -22.9600
30 C1x C 19.7374 -20.6050
31 C1x C 20.5708 -19.4801
32 C1x C 19.7585 -18.3398
33 C1x C 18.4230 -18.7600
BOND 37
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 5 6 1
6 1 6 1
7 5 7 1
8 7 8 2
9 8 9 1
10 9 10 2
11 10 11 1
12 11 12 2
13 7 12 1
14 10 13 1
15 13 14 1
16 14 15 2
17 15 16 1
18 16 17 2
19 17 18 1
20 18 19 2
21 14 19 1
22 16 20 1
23 20 21 1
24 21 22 1
25 22 23 2
26 17 23 1
27 20 24 1
28 22 25 1
29 25 26 1
30 25 27 2
31 21 28 2
32 23 29 1
33 24 30 1
34 30 31 1
35 31 32 1
36 32 33 1
37 24 33 1
|
|---|
